Combining surgery with chemotherapy significantly improves survival in GIST patients with liver metastases compared to chemotherapy alone. Median CSS and OS for combined treatment exceed 120 months, ...
Combination therapy with avelumab plus axitinib demonstrated a clinical benefit in patients with advanced gastrointestinal stromal tumour (GIST), achieving a 69.6% disease control rate and a 57.1% ...
Gastrointestinal stromal tumors (GISTs) represent a rare tumor entity that occurs in the muscular layer of the digestive tract. These tumors commonly metastasize to the liver and peritoneum, and ...
PLYMOUTH, Mass.--(BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced updated ...
Prognostic analysis of gastrointestinal stromal tumor by mitotic activity, size of tumor and mutational type of C-Kit protein No significant financial relationships to disclose. This is an ASCO ...
GISTs originate from interstitial cells of Cajal and are staged by size, location, mitotic rate, and genetic mutations, influencing treatment strategies. Diagnosis involves imaging, endoscopy, biopsy, ...
Less than 5% of GI stromal tumors (GISTs) are driven by the loss of the succinate dehydrogenase (SDH) complex, resulting in a pervasive DNA hypermethylation pattern that leads to unique clinical ...
A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results